. Author manuscript; available in PMC: 2020 May 1.

Published in final edited form as: Neurorehabil Neural Repair. 2019 Mar 27;33(5):331–344. doi: 10.1177/1545968319837289

Table 2.

Data Extracted From Reviewed Association Studies.

Study	Study Design	Dx	n	Sex		Mean Age, Years (Range or SD)	Time Since Injury	Genes Assessed	Length of Follow-up	Co-interventions	Outcome Variables	Results
Diaz-Heijtz (2018)⁵¹	Cohort	CP	33	12 F	21 M	2.2 (1.5–5)	N/A	COMT, DAT, DRD1, DRD2, DRD3	2-month drug intervention	CIMT 2 h/d × 2 months	AHA, genome analysis	Higher combined gene score associated with greater change in AHA score after CIMT
Kim (2016)⁴⁹	Cohort	Stroke	74	32 F	42 M	61.4 (14.1)	1 week	COMT, DRD1, DRD2, DRD3	6 months poststroke	Inpatient rehabilitation	FM, FIM, NIHSS, genome analysis	Those with Met(−) polymorphism on COMT gene had higher FM and FIM scores than Met(+) group at discharge, and 3 and 6 months postinjury
Liepert (2013)⁵⁰	Cohort	Stroke	83	30 F	53 M	68.7	19 days (7 COMT days to 3 months)		6 months poststroke	Inpatient rehabilitation	RMA, BI, genome analysis	Those with Met/Met polymorphism were worse on RMA and BI than those with Val/Val, with performance in Val/ Met group between the other two.

Abbreviations: M, male; F, female; SD, standard deviation; Dx, diagnosis; CP, cerebral palsy; COMT, catechol-O-methyltransferase; DAT, dopamine transporter, DRD1–3, dopamine receptor D1-D3; AHA, Assisting Hand Assessment; FM, Fugl-Meyer Assessment; FIM, Functional Independence Measure; NIHSS, National Institutes of Health Stroke Scale; RMA, Rivermead Motor Assessment; BI, Barthal Index; CIMT, Constraint-Induced Movement Therapy; Met, methionine; Val, valine.